Acute PainNCT02430818
Comparing Ketamine and Morphine in the Treatment of Acute Fracture Pain
A study testing ketamine and morphine in people with Acute Pain and Fractures, run by Washington University School of Medicine at 1 site in United States.
Trial summary
Opioid pain medications such as morphine and dilaudid are commonly used in emergency departments to treat pain in patients. Physicians are familiar with the side effects of these medications; the most concerning of which is slowing or stopping a patient's breathing, as well as dangerously lowering their blood… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Acute Pain, Fractures
- What is being tested?
- ketamine and morphine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2015to Sep 2017
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Eligible Long bone fractures. This will include:
- Humerus
- Tibia
- Fibula
- Femur
- Radius
- Ulna
Who cannot join
- Injuries older than 24 hours
- Avulsion fractures
- History of substance abuse
- History of chronic opioid dependence
- Pregnancy
- Demonstrates signs of intoxication
Show all 9Show fewer
- Allergic to ketamine or opioids
- Patients unable to consent
- Hemodynamically unstable (SBP >180mmHg or <100mgHg, HR >130bpm, Respiratory rate <10, oxygen saturations <90%
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparing the Effectiveness of Low-dose Ketamine With Morphine to Treat Pain in Patients With Long Bone Fractures
Opioid pain medications such as morphine and dilaudid are commonly used in emergency departments to treat pain in patients. Physicians are familiar with the side effects of these medications; the most concerning of which is slowing or stopping a patient's breathing, as well as dangerously lowering their blood pressure. An alternative medication is ketamine. This medication is also commonly used in the emergency department, although it is typically used to help sedate patients for uncomfortable procedures. Ketamine has also been used for pain control, but in a much lower dosage that does not sedate patients. When used for analgesia, it has typically been administered in combination with opioid pain medications. To date, there is no study that looks at the effectiveness and safety of using a low dose ketamine alone in comparison to the use of morphine. The purpose of this study is to measure how well low-dose ketamine treats pain compared to morphine and to look at how often serious side effects are seen with each medication.
Read the detailed description
Opioid analgesia is the standard of care for treating moderate to severe pain in the emergency department. It is an effective medication that most practitioners are familiar using. Opioid use is not without risk, however. In managing acute pain, patients may experience hypotension, respiratory depression, hypoxia, nausea and vomiting, dysphoria, and itching. Patients at risk for respiratory depression include those with advanced age, renal failure, or treated with multiple other sedatives.
The current recommended dose for opioid administration for acute pain management is approximately 0.1 mg/kg as a loading dose, although some sources recommend up to 10 mg for patients weighing more than 50 kg. (Ducharme 2011; Yak 2011) A single center study demonstrated that patients received an average of 0.08 mg/kg of morphine, which did not adequately control their pain; no patient received an initial dose of 10 mg.(Bijur 2012) A post-operative pain study demonstrated that patients needed on average 12 mg or a mean weight-based dose of 0.17 mg/kg of morphine to achieve an acceptable level of pain reduction as determined by a 30 mm change on a visual analog scale.(Aubrun 2003) As such even if patients received 1 mg of hydromorphone, their pain would still not be adequately controlled.
Ketamine is a dissociative anesthetic that is a noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Low dose ketamine (LDK) (0.03-0.05 mg/kg) has analgesic properties by modulating opioid tolerance and hyperalgesia.(Uprety 2013) Currently, ketamine is used in the emergency department for moderate sedations and "awake" intubations. In the pre-hospital setting, it is used in the management of patients with excited delirium and pain control.(Keseg 2014)(Wiel 2014)(Jennings 2013) Benefits include fewer serious adverse effects, especially involving respiratory depression and hypotension which occurs with high-dose or repeat doses of opioids.(Jennings 2013) In addition to not causing hypotension, ketamine can elevate a patient's blood pressure, which may be useful in some circumstances.(Johansson 2009) Emergence delirium is associated with ketamine; this is a rare adverse event and is usually alleviated with benzodiazepines. Additionally, LDK is unlikely to cause the emergence delirium or the dissociation usually associated with larger doses. Another potential complication is laryngospasm. Fortunately, this too is rare and in most cases, patients are easily bagged through the event.
LDK is efficacious in reducing multiple types of pain in a variety of settings. Ketamine infusions can reduce pain from vaso-occlusive pain crises seen in patients with sickle cell anemia.(Uprety 2013)(Neri 2013)(Jennings 2013) In the postoperative setting and intensive care unit, ketamine reduced the amount of morphine required to control pain.(Galinski 2007)(Bell 2006)(Herring 2013) In out-of-hospital trauma patients, ketamine combined with morphine produced superior analgesia to morphine alone. All patients received morphine and were then randomized to receive either morphine or ketamine if further analgesia was required. Ketamine had a change in the visual analog scale (VAS) of -5.6 (CI -6.2 to -5.0) while morphine had had a change of -3.2 (CI -3.7 to -2.7).(Jennings 2012) In another pre-hospital study, ketamine was administered to 1030 patients for pain or anesthesia. No patients incurred ketamine-induced respiratory adverse events.(Bredmose 2009) Preliminary studies have also investigated LDK in the emergency department (ED). Available research mainly consists of retrospective or observational data. In an observational study performed in an urban ED in California, LDK significantly improved patient's pain without adversely effecting blood pressure, heart rate, or respiratory drive. Twenty-four patients over age 18 who received ketamine for any reason were included. Three received ketamine for sedation while the rest received it for analgesia. Most patients received opioids prior to receiving ketamine, although the opioids did not result in improved pain scores. On a scale of 0 to 10, ketamine reduced pain from 8.9 ± 2.1 to 3.9 ± 3.4 (p<0.0001).(Richards 2013) In another observational, ED based study, ketamine used as an analgesic was investigated. Thirty patients with a variety of painful complaints (abdominal pain, back pain, nephrolithiasis, biliary pain, fractures, sickle cell pain) were enrolled. Patients were initially administered a combination of hydromorphone 0.5 mg and ketamine 15 mg with rescue doses of hydromorphone 1 mg available 15 minutes and 30 minutes after the initial dose of analgesia. In 28 patients (93%), there was a clinically significant decrease of 2 or more points on a numerical rating score measured after the initial administration; 14 patients reported pain scores of 0. Fourteen patients refused any additional hydromorphone and 24 patients (80%) either refused additional hydromorphone at 15 minutes or received a dose at 15 minutes but declined a dose at 30 minutes. Dizziness, nausea, headache, and some dissociative effects were reported.(Ahern 2013) Ketamine administered for analgesia in an urban trauma center was retrospectively reviewed in 35 patients. The most common chief complaint was abscess (46%). The median dose of ketamine received was 10 mg (range 5-35 mg); opioids were co-administered in almost all cases (91%). LDK improved pain scores by at least 3 points in 19/35 patients (54%). Eight patients did not receive a post-drug administration pain score.(Lester 2010) A convenience sample of patients was enrolled in an ED based study in British Columbia. Any patients older than 6 years of age presenting with a painful condition were eligible for enrollment. Patients had to have a score of at least 50 on a 100-mm visual analog score (VAS). All patients received 0.5 mg/kg of intranasal (IN) ketamine and could receive a rescue dose of 0.25 mg/kg IN after 10 minutes for VAS > 50. Within 30 minutes, 35 patients (88%) had a decrease in VAS of at least 13 mm. Patient reported satisfaction was a mean of 7 (5-9) on a patient satisfaction scale of 1-10. Dizziness, nausea, and fatigue were all reported.(Andolfatto 2013) IN ketamine was also demonstrated as an effective analgesic in other pediatric and adult ED based studies.(Yeaman 2013)(Yeaman 2014) While ketamine has been studied in the ED, the available research has multiple limitations. Most of it consists of observational or retrospective studies. As such, there could be multiple explanations for their results due to multiple, uncontrolled confounders. In addition, most studies included patients with any painful complaint and did not have a comparison or control group. We plan to conduct a prospective, randomized study of ketamine compared to opioids in long bone fractures.
- Conditions
- Acute Pain, Fractures
- Keywords
- ketamine, emergency medicine, orthopedics
- Medical subject headings
- Acute Pain, Fractures, Bone
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Ketamine | Experimental | Ketamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum). Receives: Drug: ketamine |
| Morphine | Experimental | Morphine is an opioid that acts on opioidergic receptors to modulate pain. Participants in the opioid arm will receive 0.1 mg/kg IV of morphine (10 mg maximum). Receives: Drug: morphine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain Treatment-VAS (Visual Analog Scale)
Study outcomes involve change in participants' pain as measured by a visual analog scale. The scale is a 10 inch line from 0 to 10 inches with 10 being the most pain and 0 being no pain. There are no units on the scale; it is just a straight line from no pain (0) to the worst pain (10). We assessed at o, 15, and 60 minutes but only scored the VAS at 60 minutes.
Measured: At 0 minutes and 60 minutes
Secondary outcomes (2)
Number of Participants With an Adverse Effects
We will monitor for adverse effects and record for changes in vital signs including nausea and vomiting, hypotension, respiratory depression, laryngospasm, and emotional and psychological effects (emergence reactions).
Measured: 60 minutes
Would the Participant Would Consider Using the Drug Given to Them for Pain Relief in the Future
Patients will be assessed to determine whether the participant would consider using the drug given to them for pain relief in the future. It was measured on a likert scale from 1-5 with 1 being did not like and would not use the drug again to 5 being like and would definitely receive the medication again. There are no units. The numbers below are the total number of patients that completed this answer. This was only asked on patients that received medication as if they did not receive medication the answer would not make sense. The median value is the likert value on a scale of 1-5 with the standard deviation.
Measured: 60 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Apr 2015 (estimated)
- Study startApr 2015
- Primary completionSep 2017
- Study completionSep 2017
Why it stopped: were not able to enroll patients to a satisfactory level
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (19)Papers the sponsor has linked to this study.
- Other trials for Acute PainStudies of the same condition, open and under way.
- More trials run by Washington University School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- Washington University School of Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- MOCEP
- Responsible party
- Sponsor
- Investigators
- Nicholas Musisca, MD, Principal investigator, Physician
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02430818
- Sponsor's protocol ID
- 201501068
- Status last verified
- Apr 2019
- First submitted
- 25 Apr 2015
- Last updated
- 22 May 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Ahern TL, Herring AA, Stone MB, Frazee BW. Effective analgesia with low-dose ketamine and reduced dose hydromorphone in ED patients with severe pain. Am J Emerg Med. 2013 May;31(5):847-51. doi: 10.1016/j.ajem.2013.02.008. Epub 2013 Apr 18.
PubMed 23602757Andolfatto G, Willman E, Joo D, Miller P, Wong WB, Koehn M, Dobson R, Angus E, Moadebi S. Intranasal ketamine for analgesia in the emergency department: a prospective observational series. Acad Emerg Med. 2013 Oct;20(10):1050-4. doi: 10.1111/acem.12229.
PubMed 24127709Aubrun F, Langeron O, Quesnel C, Coriat P, Riou B. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology. 2003 Jun;98(6):1415-21. doi: 10.1097/00000542-200306000-00017.
PubMed 12766651Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004603. doi: 10.1002/14651858.CD004603.pub2.
PubMed 16437490Bijur PE, Esses D, Chang AK, Gallagher EJ. Dosing and titration of intravenous opioid analgesics administered to ED patients in acute severe pain. Am J Emerg Med. 2012 Sep;30(7):1241-4. doi: 10.1016/j.ajem.2011.06.015. Epub 2011 Sep 9.
PubMed 21908134Bredmose PP, Lockey DJ, Grier G, Watts B, Davies G. Pre-hospital use of ketamine for analgesia and procedural sedation. Emerg Med J. 2009 Jan;26(1):62-4. doi: 10.1136/emj.2007.052753.
PubMed 19104109Galinski M, Dolveck F, Combes X, Limoges V, Smail N, Pommier V, Templier F, Catineau J, Lapostolle F, Adnet F. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007 May;25(4):385-90. doi: 10.1016/j.ajem.2006.11.016.
PubMed 17499654Herring AA, Ahern T, Stone MB, Frazee BW. Emerging applications of low-dose ketamine for pain management in the ED. Am J Emerg Med. 2013 Feb;31(2):416-9. doi: 10.1016/j.ajem.2012.08.031. Epub 2012 Nov 16. No abstract available.
PubMed 23159425Jennings CA, Bobb BT, Noreika DM, Coyne PJ. Oral ketamine for sickle cell crisis pain refractory to opioids. J Pain Palliat Care Pharmacother. 2013 Jun;27(2):150-4. doi: 10.3109/15360288.2013.788599. Epub 2013 May 21.
PubMed 23692261Jennings PA, Cameron P, Bernard S, Walker T, Jolley D, Fitzgerald M, Masci K. Morphine and ketamine is superior to morphine alone for out-of-hospital trauma analgesia: a randomized controlled trial. Ann Emerg Med. 2012 Jun;59(6):497-503. doi: 10.1016/j.annemergmed.2011.11.012. Epub 2012 Jan 13.
PubMed 22243959Johansson P, Kongstad P, Johansson A. The effect of combined treatment with morphine sulphate and low-dose ketamine in a prehospital setting. Scand J Trauma Resusc Emerg Med. 2009 Nov 27;17:61. doi: 10.1186/1757-7241-17-61.
PubMed 19943920Keseg D, Cortez E, Rund D, Caterino J. The Use of Prehospital Ketamine for Control of Agitation in a Metropolitan Firefighter-based EMS System. Prehosp Emerg Care. 2015 January-March;19(1):110-115. doi: 10.3109/10903127.2014.942478. Epub 2014 Aug 25.
PubMed 25153713Lester L, Braude DA, Niles C, Crandall CS. Low-dose ketamine for analgesia in the ED: a retrospective case series. Am J Emerg Med. 2010 Sep;28(7):820-7. doi: 10.1016/j.ajem.2009.07.023. Epub 2010 Apr 2.
PubMed 20837262Neri CM, Pestieau SR, Darbari DS. Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease. Paediatr Anaesth. 2013 Aug;23(8):684-9. doi: 10.1111/pan.12172. Epub 2013 Apr 9.
PubMed 23565738Richards JR, Rockford RE. Low-dose ketamine analgesia: patient and physician experience in the ED. Am J Emerg Med. 2013 Feb;31(2):390-4. doi: 10.1016/j.ajem.2012.07.027. Epub 2012 Oct 4.
PubMed 23041484
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparing the Effectiveness of Low-dose Ketamine With Morphine to Treat Pain in Patients With Long Bone Fractures
- ClinicalTrials.gov ID
- NCT02430818
- Acronym / sponsor ID
- 201501068
- Conditions
- Acute Pain, Fractures
- Keywords
- ketamine, emergency medicine, orthopedics
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: were not able to enroll patients to a satisfactory level
- Enrolment
- 13 participants (actual)
- Lead sponsor
- Washington University School of MedicineUniversity, hospital or other
- Collaborators
- MOCEP
- Study start
- Apr 2015
- Primary completion
- Sep 2017 (actual)
- Study completion
- Sep 2017 (actual)
- First posted
- 30 Apr 2015 (estimated)
- Results
- Posted 22 May 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Opioid pain medications such as morphine and dilaudid are commonly used in emergency departments to treat pain in patients. Physicians are familiar with the side effects of these medications; the most concerning of which is slowing or stopping a patient's breathing, as well as dangerously lowering their blood pressure. An alternative medication is ketamine. This medication is also commonly used in the emergency department, although it is typically used to help sedate patients for uncomfortable procedures. Ketamine has also been used for pain control, but in a much lower dosage that does not sedate patients. When used for analgesia, it has typically been administered in combination with opioid pain medications. To date, there is no study that looks at the effectiveness and safety of using a low dose ketamine alone in comparison to the use of morphine. The purpose of this study is to measure how well low-dose ketamine treats pain compared to morphine and to look at how often serious side effects are seen with each medication.
Detailed description
Opioid analgesia is the standard of care for treating moderate to severe pain in the emergency department. It is an effective medication that most practitioners are familiar using. Opioid use is not without risk, however. In managing acute pain, patients may experience hypotension, respiratory depression, hypoxia, nausea and vomiting, dysphoria, and itching. Patients at risk for respiratory depression include those with advanced age, renal failure, or treated with multiple other sedatives.
The current recommended dose for opioid administration for acute pain management is approximately 0.1 mg/kg as a loading dose, although some sources recommend up to 10 mg for patients weighing more than 50 kg. (Ducharme 2011; Yak 2011) A single center study demonstrated that patients received an average of 0.08 mg/kg of morphine, which did not adequately control their pain; no patient received an initial dose of 10 mg.(Bijur 2012) A post-operative pain study demonstrated that patients needed on average 12 mg or a mean weight-based dose of 0.17 mg/kg of morphine to achieve an acceptable level of pain reduction as determined by a 30 mm change on a visual analog scale.(Aubrun 2003) As such even if patients received 1 mg of hydromorphone, their pain would still not be adequately controlled.
Ketamine is a dissociative anesthetic that is a noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Low dose ketamine (LDK) (0.03-0.05 mg/kg) has analgesic properties by modulating opioid tolerance and hyperalgesia.(Uprety 2013) Currently, ketamine is used in the emergency department for moderate sedations and "awake" intubations. In the pre-hospital setting, it is used in the management of patients with excited delirium and pain control.(Keseg 2014)(Wiel 2014)(Jennings 2013) Benefits include fewer serious adverse effects, especially involving respiratory depression and hypotension which occurs with high-dose or repeat doses of opioids.(Jennings 2013) In addition to not causing hypotension, ketamine can elevate a patient's blood pressure, which may be useful in some circumstances.(Johansson 2009) Emergence delirium is associated with ketamine; this is a rare adverse event and is usually alleviated with benzodiazepines. Additionally, LDK is unlikely to cause the emergence delirium or the dissociation usually associated with larger doses. Another potential complication is laryngospasm. Fortunately, this too is rare and in most cases, patients are easily bagged through the event.
LDK is efficacious in reducing multiple types of pain in a variety of settings. Ketamine infusions can reduce pain from vaso-occlusive pain crises seen in patients with sickle cell anemia.(Uprety 2013)(Neri 2013)(Jennings 2013) In the postoperative setting and intensive care unit, ketamine reduced the amount of morphine required to control pain.(Galinski 2007)(Bell 2006)(Herring 2013) In out-of-hospital trauma patients, ketamine combined with morphine produced superior analgesia to morphine alone. All patients received morphine and were then randomized to receive either morphine or ketamine if further analgesia was required. Ketamine had a change in the visual analog scale (VAS) of -5.6 (CI -6.2 to -5.0) while morphine had had a change of -3.2 (CI -3.7 to -2.7).(Jennings 2012) In another pre-hospital study, ketamine was administered to 1030 patients for pain or anesthesia. No patients incurred ketamine-induced respiratory adverse events.(Bredmose 2009) Preliminary studies have also investigated LDK in the emergency department (ED). Available research mainly consists of retrospective or observational data. In an observational study performed in an urban ED in California, LDK significantly improved patient's pain without adversely effecting blood pressure, heart rate, or respiratory drive. Twenty-four patients over age 18 who received ketamine for any reason were included. Three received ketamine for sedation while the rest received it for analgesia. Most patients received opioids prior to receiving ketamine, although the opioids did not result in improved pain scores. On a scale of 0 to 10, ketamine reduced pain from 8.9 ± 2.1 to 3.9 ± 3.4 (p<0.0001).(Richards 2013) In another observational, ED based study, ketamine used as an analgesic was investigated. Thirty patients with a variety of painful complaints (abdominal pain, back pain, nephrolithiasis, biliary pain, fractures, sickle cell pain) were enrolled. Patients were initially administered a combination of hydromorphone 0.5 mg and ketamine 15 mg with rescue doses of hydromorphone 1 mg available 15 minutes and 30 minutes after the initial dose of analgesia. In 28 patients (93%), there was a clinically significant decrease of 2 or more points on a numerical rating score measured after the initial administration; 14 patients reported pain scores of 0. Fourteen patients refused any additional hydromorphone and 24 patients (80%) either refused additional hydromorphone at 15 minutes or received a dose at 15 minutes but declined a dose at 30 minutes. Dizziness, nausea, headache, and some dissociative effects were reported.(Ahern 2013) Ketamine administered for analgesia in an urban trauma center was retrospectively reviewed in 35 patients. The most common chief complaint was abscess (46%). The median dose of ketamine received was 10 mg (range 5-35 mg); opioids were co-administered in almost all cases (91%). LDK improved pain scores by at least 3 points in 19/35 patients (54%). Eight patients did not receive a post-drug administration pain score.(Lester 2010) A convenience sample of patients was enrolled in an ED based study in British Columbia. Any patients older than 6 years of age presenting with a painful condition were eligible for enrollment. Patients had to have a score of at least 50 on a 100-mm visual analog score (VAS). All patients received 0.5 mg/kg of intranasal (IN) ketamine and could receive a rescue dose of 0.25 mg/kg IN after 10 minutes for VAS > 50. Within 30 minutes, 35 patients (88%) had a decrease in VAS of at least 13 mm. Patient reported satisfaction was a mean of 7 (5-9) on a patient satisfaction scale of 1-10. Dizziness, nausea, and fatigue were all reported.(Andolfatto 2013) IN ketamine was also demonstrated as an effective analgesic in other pediatric and adult ED based studies.(Yeaman 2013)(Yeaman 2014) While ketamine has been studied in the ED, the available research has multiple limitations. Most of it consists of observational or retrospective studies. As such, there could be multiple explanations for their results due to multiple, uncontrolled confounders. In addition, most studies included patients with any painful complaint and did not have a comparison or control group. We plan to conduct a prospective, randomized study of ketamine compared to opioids in long bone fractures.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ketamine | Experimental | Drug: ketamineKetamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum). |
| Morphine | Experimental | Drug: morphineMorphine is an opioid that acts on opioidergic receptors to modulate pain. Participants in the opioid arm will receive 0.1 mg/kg IV of morphine (10 mg maximum). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Eligible Long bone fractures. This will include:
- Humerus
- Tibia
- Fibula
- Femur
Key exclusion criteria (9 listed)
- Injuries older than 24 hours
- Avulsion fractures
- History of substance abuse
- History of chronic opioid dependence
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ketamine | Drug | Ketamine |
| morphine | Drug | Morphine |
Primary outcome
Pain Treatment-VAS (Visual Analog Scale)
Time frame: At 0 minutes and 60 minutes
Study outcomes involve change in participants' pain as measured by a visual analog scale. The scale is a 10 inch line from 0 to 10 inches with 10 being the most pain and 0 being no pain. There are no units on the scale; it is just a straight line from no pain (0) to the worst pain (10). We assessed at o, 15, and 60 minutes but only scored the VAS at 60 minutes.
2 secondary outcomes
Number of Participants With an Adverse Effects
Time frame: 60 minutes
Would the Participant Would Consider Using the Drug Given to Them for Pain Relief in the Future
Time frame: 60 minutes
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 23602757Ahern TL, Herring AA, Stone MB, Frazee BW. Effective analgesia with low-dose ketamine and reduced dose hydromorphone in ED patients with severe pain. Am J Emerg Med. 2013 May;31(5):847-51. doi: 10.1016/j.ajem.2013.02.008. Epub 2013 Apr 18.
- Background: PubMed 24127709Andolfatto G, Willman E, Joo D, Miller P, Wong WB, Koehn M, Dobson R, Angus E, Moadebi S. Intranasal ketamine for analgesia in the emergency department: a prospective observational series. Acad Emerg Med. 2013 Oct;20(10):1050-4. doi: 10.1111/acem.12229.
- Background: PubMed 12766651Aubrun F, Langeron O, Quesnel C, Coriat P, Riou B. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology. 2003 Jun;98(6):1415-21. doi: 10.1097/00000542-200306000-00017.
- Background: PubMed 16437490Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004603. doi: 10.1002/14651858.CD004603.pub2.
- Background: PubMed 21908134Bijur PE, Esses D, Chang AK, Gallagher EJ. Dosing and titration of intravenous opioid analgesics administered to ED patients in acute severe pain. Am J Emerg Med. 2012 Sep;30(7):1241-4. doi: 10.1016/j.ajem.2011.06.015. Epub 2011 Sep 9.
- Background: PubMed 19104109Bredmose PP, Lockey DJ, Grier G, Watts B, Davies G. Pre-hospital use of ketamine for analgesia and procedural sedation. Emerg Med J. 2009 Jan;26(1):62-4. doi: 10.1136/emj.2007.052753.
- Background: PubMed 17499654Galinski M, Dolveck F, Combes X, Limoges V, Smail N, Pommier V, Templier F, Catineau J, Lapostolle F, Adnet F. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007 May;25(4):385-90. doi: 10.1016/j.ajem.2006.11.016.
- Background: PubMed 23159425Herring AA, Ahern T, Stone MB, Frazee BW. Emerging applications of low-dose ketamine for pain management in the ED. Am J Emerg Med. 2013 Feb;31(2):416-9. doi: 10.1016/j.ajem.2012.08.031. Epub 2012 Nov 16. No abstract available.
- Background: PubMed 23692261Jennings CA, Bobb BT, Noreika DM, Coyne PJ. Oral ketamine for sickle cell crisis pain refractory to opioids. J Pain Palliat Care Pharmacother. 2013 Jun;27(2):150-4. doi: 10.3109/15360288.2013.788599. Epub 2013 May 21.
- Background: PubMed 22243959Jennings PA, Cameron P, Bernard S, Walker T, Jolley D, Fitzgerald M, Masci K. Morphine and ketamine is superior to morphine alone for out-of-hospital trauma analgesia: a randomized controlled trial. Ann Emerg Med. 2012 Jun;59(6):497-503. doi: 10.1016/j.annemergmed.2011.11.012. Epub 2012 Jan 13.
- Background: PubMed 19943920Johansson P, Kongstad P, Johansson A. The effect of combined treatment with morphine sulphate and low-dose ketamine in a prehospital setting. Scand J Trauma Resusc Emerg Med. 2009 Nov 27;17:61. doi: 10.1186/1757-7241-17-61.
- Background: PubMed 25153713Keseg D, Cortez E, Rund D, Caterino J. The Use of Prehospital Ketamine for Control of Agitation in a Metropolitan Firefighter-based EMS System. Prehosp Emerg Care. 2015 January-March;19(1):110-115. doi: 10.3109/10903127.2014.942478. Epub 2014 Aug 25.
Related trials for Acute Pain
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruitingPhase 2
A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)
Pain Management
Not yet recruitingPhase 2
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
Healthy Volunteers
Not yet recruiting
Post-operative Pain and Clinical Outcome After Single-cone Obturation With a Calcium Silicate-based Versus Epoxy Resin Sealer
Post Operative Pain, Acute, Irreversible Pulpitis (Toothache)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicholas Musisca, MD principal investigator
Physician
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ketamine and morphine in people with Acute Pain and Fractures, run by Washington University School of Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 22 May 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 May 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain Treatment-VAS (Visual Analog Scale) (time frame: At 0 minutes and 60 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02430818, which also lists 19 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2019.